GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » GENinCode PLC (LSE:GENI) » Definitions » Revenue

GENinCode (LSE:GENI) Revenue : £2.16 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is GENinCode Revenue?

GENinCode's revenue for the six months ended in Dec. 2023 was £1.21 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was £2.16 Mil. GENinCode's Revenue per Share for the six months ended in Dec. 2023 was £0.01. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was £0.02.

During the past 12 months, the average Revenue per Share Growth Rate of GENinCode was 53.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 32.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 5 years, GENinCode's highest 3-Year average Revenue per Share Growth Rate was 32.00% per year. The lowest was 32.00% per year. And the median was 32.00% per year.


GENinCode Revenue Historical Data

The historical data trend for GENinCode's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GENinCode Revenue Chart

GENinCode Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
- 0.96 1.15 1.43 2.16

GENinCode Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Revenue Get a 7-Day Free Trial 0.55 0.66 0.77 0.95 1.21

Competitive Comparison of GENinCode's Revenue

For the Diagnostics & Research subindustry, GENinCode's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GENinCode's Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, GENinCode's Revenue distribution charts can be found below:

* The bar in red indicates where GENinCode's Revenue falls into.



GENinCode Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £2.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GENinCode  (LSE:GENI) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


GENinCode Revenue Related Terms

Thank you for viewing the detailed overview of GENinCode's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


GENinCode (LSE:GENI) Business Description

Traded in Other Exchanges
N/A
Address
Oxford Science Park, John Eccles House, Robert Robertson Avenue, Oxford, GBR, OX4 4GP
GENinCode PLC is engaged in the genetic risk assessment, prediction, and prevention of cardiovascular diseases including coronary artery diseases such as angina and myocardial infarction (heart attack), stroke, heart failure, hypertension, and other vascular heart diseases. The company's current product portfolio comprises Cardio inCode, LiPID inCode, SuDD inCode, and Thrombo inCode. The company has only one reportable segment being sale of kits and provision of support services. The Geographic Markets of the group are Chile, France, Italy, Sweden, Mexico, Spain and United Kingdom.